« Back to Record
Citation APA

Perez, E. A., Yardley, D., Potter, D. D., Mailliez, A., Moreno-Aspitia, A., Ahn, J. S., Zhao, C., Hoch, U., Tagliaferri, M., Hannah, A. L., Cortes, J., Awada, A., O'Shaughnessy, J., Rugo, H., Twelves, C., Im, S. A., Gómez-Pardo, P., Schwartzberg, L. L., & Diéras, V. (2015). Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): A randomised, open-label, multicentre, phase 3 trial. Lancet oncology, 16(15), 1556-1568. doi:10.1016/S1470-2045(15)00332-0


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/231597

Perez, E. A., Yardley, D., Potter, D. D., Mailliez, A., Moreno-Aspitia, A., Ahn, J. S., Zhao, C., Hoch, U., Tagliaferri, M., Hannah, A. L., Cortes, J., Awada, A., O'Shaughnessy, J., Rugo, H., Twelves, C., Im, S. A., Gómez-Pardo, P., Schwartzberg, L. L., & Diéras, V. (2015). Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): A randomised, open-label, multicentre, phase 3 trial. Lancet oncology, 16(15), 1556-1568. doi:10.1016/S1470-2045(15)00332-0